Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial.

被引：2
|
作者：
O'Brien, Mary E. R.
Eberhardt, Wilfried Ernst Erich
Altorki, Nasser K.
Spigel, David R.
Crino, Lucio
Tsai, Chun-Ming
Cho, Eun Kyung
Kim, Joo-Hang
Szczesna, Aleksandra
Hoffman, Philip C.
Burghuber, Otto
Keshavjee, Shaf
Orlov, Sergey
Serwatowski, Piotr
Wang, Jiuzhou
Foley, Margaret A.
Horan, Julie D.
Park, Jung Wook
Shepherd, Frances A.
Kelly, Karen
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol,Ruhrlandklin, Essen, Germany
[3] New Presbyterian Hosp Weill Cornell Med Coll, New York, NY USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Perugia, I-06100 Perugia, Italy
[6] Taipei Vet Gen Hosp, Dept Chest Med, Div Thorac Oncol, Taipei, Taiwan
[7] Natl Yang Ming Univ, Dept Med, Taipei 112, Taiwan
[8] Gachon Univ, Gil Med Ctr, Inchon, South Korea
[9] Yonsei Univ Heath Syst, Yonsei Canc Ctr, Seoul, South Korea
[10] Mazowieckie Ctr Leczenia Chorob Pluc, Otwock, Poland
[11] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[12] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria
[13] Univ Hlth Network, Princess Margaret Canc Ctr, Div Thorac Surg, Toronto, ON, Canada
[14] St Petersburg Med Univ, St Petersburg, Russia
[15] Specjalisty Szpital, Szczecin, Poland
[16] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[17] Novella Clin, Boulder, CO USA
[18] Astellas Pharma Global Dev, Northbrook, IL USA
[19] Princess Margaret Canc Ctr, Toronto, ON, Canada
[20] UC Davis Comprehens Canc Ctr, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.7535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7535
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial.
    Shepherd, Frances A.
    Altorki, Nasser K.
    Eberhardt, Wilfried Ernst Erich
    O'Brien, Mary E. R.
    Spigel, David R.
    Crino, Lucio
    Tsai, Chun-Ming
    Kim, Joo-Hang
    Cho, Eun Kyung
    Szczesna, Aleksandra
    Burghuber, Otto
    Hoffman, Philip C.
    Keshavjee, Shaf
    Orlov, Sergey
    Serwatowski, Piotr
    Wang, Jiuzhou
    Foley, Margaret A.
    Horan, Julie D.
    Richardson, Frank C.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results
    Altorki, N. K.
    O'brien, M. E. R.
    Eberhardt, W. E. E.
    Richardson, F. C.
    Wang, J.
    Foley, M. A.
    Horan, J. D.
    Shepherd, F. A.
    Kelly, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S2 - S3
  • [3] Symptom response in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib: Quality of life analysis of the NCICCTG BR.21 trial.
    Bezjak, A
    Shepherd, F
    Tu, D
    Clark, G
    Santabarbara, P
    Pater, J
    Seymour, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 625S - 625S
  • [4] Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression
    Reguart, Noemi
    Isla, Dolores
    Cardenal, Felipe
    Cardona, Andres
    Palmero, Ramon
    Moran, Teresa
    Rolfo, Christian Diego
    Nadal, Ernesto Samuel
    Massuti, Tomeu
    Montanes, Ana
    Queralt, Cristina
    Taron, Miquel
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S708 - S708
  • [5] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [6] Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT)
    Boyer, M. J.
    Blackhall, F. H.
    Park, K.
    Barrios, C. H.
    Krzakowski, M. J.
    Taylor, I.
    Liang, J. Q.
    Denis, L. J.
    O'Connell, J. P.
    Ramalingam, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [7] Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small cell lung cancer (NSCLC)
    Grossi, F.
    Brianti, A.
    Defferrari, C.
    Loprevite, M.
    Catania, G.
    Pronzato, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] SAFETY AND TOLERABILITY OF ERLOTINIB (E) IN NON-SMALL CELL LUNG CANCER (NSCLC) ELDERLY PATIENTS (PTS) AFTER A PRIOR CHEMOTHERAPY REGIMEN: A MONO-INSTITUTIONAL EXPERIENCE
    Pietrantonio, Filippo
    Vitali, Milena
    Zilembo, Nicoletta
    Bichisao, Ettore
    Platania, Marco
    Buzzoni, Roberto
    Barone, Gloria
    Guadalupi, Valentina
    Bajetta, Emilio
    ANNALS OF ONCOLOGY, 2009, 20
  • [9] Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E)
    Villaflor, V. M.
    Kanteti, R.
    Watson, S. M.
    Karrison, T.
    Vokes, E. E.
    Salgia, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Erlotinib in non-small cell lung cancer (NSCLC): Interim safety analysis of the TRUST study
    Gatzemeier, U.
    Ardizzoni, A.
    Horwood, K.
    van Meerbeeck, J.
    Magyar, P.
    Gottfried, M.
    Arrieta, O.
    Krzakowski, M.
    Franke, F.
    van Zandwijk, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345